Eflornithine is a topic covered in the Johns Hopkins ABX Guide.
To view the entire topic, please sign in or purchase a subscription.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
FDA
- Eflornithine (IV): no longer commercially available in the U.S.
- Treatment of unwanted facial hair in women (topical cream)
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- African trypanosomiasis (sleeping sickness):Second-stage T. b. gambiense
- Eflornithine is not effective against T. b. rhodesiense(East African form of the diseases)
- Drug can be obtained from CDC by contacting the Division of Parasitic Diseases and Malaria (telephone, 404-718-4745; email, parasites@cdc.gov).
-- To view the remaining sections of this topic, please sign in or purchase a subscription --
Last updated: June 3, 2017
Citation
* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Eflornithine
ID - 540184
A1 - Avdic,Edina,Pharm.D.
AU - Pham,Paul,Pharm.D.
Y1 - 2017/06/03/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540184/all/Eflornithine
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -